Bharat Biotech approaches DCGI, seeks Covaxin's removal from 'clinical trial mode'

The vaccine was granted approval “for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode”, which meant that beneficiaries would have to give consent before they were vaccinated and there would be regular follow up. Such persons would also not receive the placebo.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news